← Back to Search

Hearing Aid

Hearing Aids for Hearing Loss (IHAT Trial)

N/A
Recruiting
Led By Anu Sharma, PhD
Research Sponsored by University of Colorado, Denver
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Adult onset, bilateral, mild-to-moderate sensorineural hearing loss documented by audiological evaluation
Aged 40 years or older
Must not have
Asymmetrical hearing loss
Diagnosed neurological condition such as dementia or Parkinson's disease or a score lower than 25 on the Montreal Cognitive Assessment
Timeline
Screening 3 weeks
Treatment Varies
Follow Up t1= 6 months post intervention, t2= 12 months post intervention
Awards & highlights
No Placebo-Only Group

Summary

"This trial will compare over-the-counter (OTC) hearing aids to prescription hearing aids fitted by specialists in people with mild to moderate hearing loss. The study will look at how each type of hearing aid

Who is the study for?
The IHAT study is for individuals with mild to moderate hearing loss. It's designed to compare different ways of getting hearing aids, including over-the-counter options and those fitted by specialists.
What is being tested?
This trial tests four service models for providing hearing aids: HA-HCP (prescription), OTC-R (regular over-the-counter), OTC-HCP (over-the-counter with healthcare professional advice), and OTC-SF (self-fitting). The impact on user experience, behavior, cognition, and brain activity will be evaluated.
What are the potential side effects?
While traditional side effects are not applicable in this context as it involves non-invasive devices rather than drugs or surgery, users may experience discomfort or dissatisfaction with the device fit or function.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have adult-onset hearing loss in both ears, confirmed by a hearing test.
Select...
I am 40 years old or older.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have hearing loss that is worse in one ear.
Select...
I have a neurological condition like dementia or Parkinson's, or scored below 25 on a cognitive test.
Select...
My hearing loss is too severe for regular hearing aids.
Select...
I have a middle ear disorder.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~t1= 6 months post intervention, t2= 12 months post intervention
This trial's timeline: 3 weeks for screening, Varies for treatment, and t1= 6 months post intervention, t2= 12 months post intervention for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Abbreviated Profile of Hearing Aid Benefit (APHAB)
Secondary study objectives
Connected Speech Test (CST)
Patient Global Impression of Change (PGI-C)
Quick Speech in Noise (QuickSIN)
+2 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

4Treatment groups
Experimental Treatment
Active Control
Group I: OTC-RExperimental Treatment1 Intervention
Group II: OTC-HCPExperimental Treatment1 Intervention
Group III: OTC-SFActive Control1 Intervention
Group IV: HA-HCPActive Control1 Intervention

Find a Location

Who is running the clinical trial?

University of Colorado, DenverLead Sponsor
1,806 Previous Clinical Trials
2,822,622 Total Patients Enrolled
National Institute on Deafness and Other Communication Disorders (NIDCD)NIH
353 Previous Clinical Trials
181,197 Total Patients Enrolled
1 Trials studying Neonatal Hearing Loss
236 Patients Enrolled for Neonatal Hearing Loss
Anu Sharma, PhDPrincipal InvestigatorUniversity of Colorado, Boulder
~187 spots leftby Dec 2028